Developer docs
API playgroundTry for free, no card

Search company profiles

Orchestra Life Sciences

Full company profile

uuid000g7jw

Namestring
Orchestra Life Sciences
Legal namestring
Orchestra Life Sciences, LLC
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Orchestra Life Sciences is a privately held technical consultancy founded in 2022 and headquartered at the Philadelphia Navy Yard, serving pharmaceutical and biotechnology companies developing radiopharmaceuticals, cell and gene therapies, regenerative medicines, and nuclear medicine products for cancer and rare disease. The firm deploys subject matter experts and consultants to deliver end-to-end support across seven integrated service lines: business strategy, engineering solutions, process and analytical development, capital projects, supply chain, quality and regulatory, and operations excellence. Its team brings over 500 years of combined nuclear medicine expertise and 100+ years in cell and gene therapy, with senior leadership including co-founders Emilie Pelletier (CEO), Sumit Verma, and Castor Armesto (CSO), plus a European President drawn from NRG's Executive Board.

The company's core technology and intellectual property center on advanced therapy manufacturing readiness, including facility design for hot cells, cyclotrons, isolators, containment systems, and process skids, as well as a proprietary TAG1 Generator intended to unlock Lead-212 (Pb-212) supply for targeted alpha therapy trials in collaboration with Precirix. Revenue is generated through professional services engagements, project-based work, and ongoing advisory relationships with enterprise clients, with pricing quote-based and not publicly disclosed. Strategic partnerships with Life Couriers (radiopharma logistics) and BioCentriq ($12M CAPEX cell therapy facility) extend the firm beyond pure advisory into integrated delivery.

In 2025–2026, Orchestra relocated from Montreal to Philadelphia's Navy Yard, expanded into Europe under a dedicated President, and announced a 2026 Workforce Development Center to address a documented nationwide shortage of 400–600 production operators and 400–800 QA/QC technicians in advanced therapy manufacturing. The firm operates as an LLC, is founder-owned without disclosed institutional investment, and supports 30+ life sciences clients across North America and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCreve Coeur, United States
HQ citystring
Creve Coeur
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical consulting services, radiopharmaceutical manufacturing, cell gene therapy consulting, advanced therapy manufacturing, GMP regulatory compliance
Industry2 codes
PRIMARYHLAGAKAB
CMC Regulatory Affairs (Modules 2/3, Variations, Post-Approval CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAOAK
CMC, Process Development & Tech Transfer Staffing FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
NAICS code2 codes
  • Other Scientific and Technical Consulting Services54169
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Life Sciences Technical Consulting
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Technical Consulting Services
TypeProfessional Services
Description

The company provides strategic support and scientific expertise to advance pharmaceutical therapies for cancer and rare disease. Services include business strategy, engineering solutions, process and analytical development, capital projects, supply chain, quality and regulatory, and operations excellence. Revenue is generated through consulting engagements, project-based work, and ongoing advisory relationships with clients in the advanced therapy sector.

orchestralifesciences.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Orchestra Life Sciences is a technical consultancy providing strategic support and scientific expertise to pharmaceutical companies developing advanced therapies. Its core offering spans seven integrated service lines—Business Strategy, Engineering Solutions, Process & Analytical Development, Capital Projects, Supply Chain, Quality & Regulatory, and Operations Excellence—delivered alongside an ATMP Laboratory Services division and a Workforce Development Center for advanced therapy manufacturing talent.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Expanded from 4-person team to 60+ employees and consultants within 3 years
+2 more records
Product overview1 text field

Orchestra Life Sciences is a technical consultancy offering a unified portfolio of strategic and scientific services organized around the core mission of advancing pharmaceutical therapies for cancer and rare disease. The company's offerings span seven integrated service lines — Business Strategy, Engineering Solutions, Process & Analytical Development, Capital Projects, Supply Chain, Quality & Regulatory, and Operations Excellence — which together provide end-to-end support from early-stage development through commercial-scale manufacturing. Supporting these service lines are educational resources (the Radiopharma Brochure and Cyclotron Ebook), a dedicated ATMP Laboratory Services division for process and bioanalytical development, and a Workforce Development Center launching in 2026 to address talent gaps in advanced therapy manufacturing. The services are designed to be delivered in concert, with each capability reinforcing the others to enable clients to move therapies from concept to commercialization.

Product and service10 records
1Business Strategy Consulting
CategoryStrategy Consulting
Description

Strategic consulting service helping advanced therapy developers align business strategies, regulatory approaches, engineering processes, and go-to-market plans; designed for pharmaceutical and biotech companies in nuclear medicine, radiation oncology, cell and gene therapy, regenerative medicine, and biotechnology.

2Engineering Solutions
CategoryEngineering Consulting
Description

Engineering consulting supporting facility design, construction, and optimization for advanced therapy manufacturing, including hot cells, cyclotrons, isolators, containment systems, and process skids; intended for pharmaceutical and biotech companies building advanced therapy facilities.

3Process & Analytical Development
CategoryProcess and Analytical Development
Description

Technical consulting for process development and analytical method development across cell therapy, gene therapy, and radiopharmaceuticals from conception through commercialization; aimed at developers needing manufacturing process and analytical readiness.

4Capital Projects
CategoryCapital Project Consulting
Description

End-to-end capital project solutions for specialized advanced therapy facilities, taking projects from feasibility studies through cGMP qualification while optimizing regulatory compliance, costs, and timelines; intended for pharmaceutical and biotech developers building or expanding manufacturing capacity.

5Supply Chain Consulting
CategorySupply Chain Consulting
Description

Supply chain planning and optimization for radiopharmaceutical and advanced therapy programs, including isotope sourcing strategy for Ac-225, Lu-177, and Pb-212; serves developers needing reliable access to scarce isotopes and raw materials.

6Quality & Regulatory Services
CategoryQuality and Regulatory Consulting
Description

Comprehensive quality, compliance, and regulatory affairs services including FDA compliance, ICH standards alignment, GMP audits, quality management system implementation, regulatory pathway development, and IND/IMPD/BLA submission support; serves developers of advanced therapies including radiopharmaceuticals, cell and gene therapies, and biologics.

7Operations Excellence
CategoryOperations Consulting
Description

Consulting to drive operational efficiency, scalable processes, and repeatable execution frameworks for GMP-regulated advanced therapy manufacturing environments; serves developers scaling from clinical to commercial production.

8ATMP Laboratory Services
CategoryLaboratory Services
Description

Process and analytical development and laboratory services for advanced therapeutic medicinal products (ATMPs) including cell therapy, gene therapy, and biologics; covers bioanalytical assays such as potency assays, flow cytometry, cell-based assays, and cell banking for developers needing laboratory support.

9Workforce Development Center
CategoryWorkforce Training Program
Description

A specialized workforce development platform providing hands-on training for operations, quality control, and quality assurance roles in cell and gene therapy, radiopharmaceutical manufacturing, and nuclear medicine production; co-located with Orchestra's Philadelphia Navy Yard headquarters and aimed at addressing the nationwide shortage of production operators and QA/QC technicians.

10TAG1 Generator
CategoryRadiopharmaceutical Isotope Production Technology
Description

A proprietary generator designed to unlock the supply of Lead-212 (Pb-212) for pre-clinical and clinical trials of targeted alpha therapies in cancer treatment; supports Orchestra's radiopharmaceutical clients and partners such as Precirix.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-01-14
Description

Strategic partnership to support BioCentriq's Princeton, NJ cell therapy facility development. Orchestra provides comprehensive technical expertise for facility design, implementation of advanced manufacturing technologies, development of integrated digital ecosystem, and optimization of facility design to meet FDA and EU GMP regulatory requirements. The collaboration supports BioCentriq's $12M CAPEX investment for facility optimization and digital integration to enhance cell therapy development and GMP manufacturing capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-17
Description

Strategic partnership to enhance supply chain capabilities for the distribution of life-saving cancer treatments. Life Couriers, a global leader in specialized healthcare logistics, brings expertise in time-sensitive transport of medical isotopes and radiopharmaceuticals. The partnership leverages Life Couriers' global logistics network and Control Towers for real-time monitoring to streamline logistics between therapy developers and patients, minimizing delays and ensuring timely delivery of advanced therapies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-08
Description

Strategic collaboration to expand access to Lead-212 (Pb-212) radioisotope for targeted alpha therapy in cancer treatment. Orchestra's TAG1 generator is designed to unlock Pb-212 supply for pre-clinical and clinical trials. The partnership combines Precirix's precision radiopharmaceutical expertise using camelid single-domain antibodies with Orchestra's proficiency in isotope production, driving new R&D initiatives and breakthroughs in cancer therapy.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large global CRO offering regulatory consulting, CMC, clinical development, and commercialization services. Overlaps with Orchestra's regulatory and CMC work, but at vastly greater scale and across broader therapeutic areas.

TypeDirect peer
Description

Regulatory, compliance, and quality consulting firm supporting pharma, biotech, and medical device companies. Closely matches Orchestra's CMC/regulatory and quality systems offering for advanced therapy developers.

3CRB
TypeDirect peer
Description

Engineering, architecture, and consulting firm specializing in life sciences facility design and construction. Directly comparable to Orchestra's Engineering Solutions, Capital Projects, and Operations Excellence service lines, especially for advanced therapy and GMP facility work.

TypeDirect peer
Description

Specialized services and CDMO supporting radiopharmaceutical, cell therapy, and biomarker-driven programs. Directly comparable to Orchestra's radiopharma and cell/gene therapy manufacturing consulting practice.

TypeBroad incumbent
Description

World's largest CRO with broad regulatory, quality, and technology services for pharma. Comparable on regulatory/CMC consulting but serves a much wider client base and modality set than Orchestra.

TypeEmerging player
Description

Life sciences training and workforce development provider for pharma manufacturing. Comparable to Orchestra's planned Workforce Development Center for cell/gene therapy and radiopharma operators, although Skillpad is more established in the UK and Europe.

TypeDirect peer
Description

Independent regulatory and CMC consulting firm serving pharma and biotech globally. Comparable to Orchestra's Quality & Regulatory and Process & Analytical Development services, particularly for novel modalities and ATMPs.

TypeBroad incumbent
Description

Global high-tech facility engineering and construction firm with a large life sciences practice. Comparable to Orchestra's Engineering Solutions and Capital Projects offerings for GMP and radiopharma facility builds, but at materially greater scale.

TypeDirect peer
Description

Regulatory affairs and quality compliance consulting firm serving pharma and biotech. Comparable to Orchestra's Quality & Regulatory Services line, including CMC, IND/IMPD/BLA support, and GxP compliance work.

TypeDirect peer
Description

Life sciences consulting firm offering regulatory, quality, engineering, and digital services to pharma and biotech. Overlaps with Orchestra's integrated seven-service platform for advanced therapy manufacturers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Orchestra Life Sciences

Life Sciences Technical Consultingorchestralifesciences.com

What Orchestra Life Sciences does

Orchestra Life Sciences is a privately held technical consultancy founded in 2022 and headquartered at the Philadelphia Navy Yard, serving pharmaceutical and biotechnology companies developing radiopharmaceuticals, cell and gene therapies, regenerative medicines, and nuclear medicine products for cancer and rare disease. The firm deploys subject matter experts and consultants to deliver end-to-end support across seven integrated service lines: business strategy, engineering solutions, process and analytical development, capital projects, supply chain, quality and regulatory, and operations excellence. Its team brings over 500 years of combined nuclear medicine expertise and 100+ years in cell and gene therapy, with senior leadership including co-founders Emilie Pelletier (CEO), Sumit Verma, and Castor Armesto (CSO), plus a European President drawn from NRG's Executive Board.

The company's core technology and intellectual property center on advanced therapy manufacturing readiness, including facility design for hot cells, cyclotrons, isolators, containment systems, and process skids, as well as a proprietary TAG1 Generator intended to unlock Lead-212 (Pb-212) supply for targeted alpha therapy trials in collaboration with Precirix. Revenue is generated through professional services engagements, project-based work, and ongoing advisory relationships with enterprise clients, with pricing quote-based and not publicly disclosed. Strategic partnerships with Life Couriers (radiopharma logistics) and BioCentriq ($12M CAPEX cell therapy facility) extend the firm beyond pure advisory into integrated delivery.

In 2025–2026, Orchestra relocated from Montreal to Philadelphia's Navy Yard, expanded into Europe under a dedicated President, and announced a 2026 Workforce Development Center to address a documented nationwide shortage of 400–600 production operators and 400–800 QA/QC technicians in advanced therapy manufacturing. The firm operates as an LLC, is founder-owned without disclosed institutional investment, and supports 30+ life sciences clients across North America and Europe.

Orchestra Life Sciences firmographics

Firmographics
Name
Orchestra Life Sciences
Legal name
Orchestra Life Sciences, LLC
Website
https://orchestralifesciences.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Orchestra Life Sciences industry classification

Industry
Product category
Life Sciences Technical Consulting
NAICS
Other Scientific and Technical Consulting Services (54169), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAKAB
CMC Regulatory Affairs (Modules 2/3, Variations, Post-Approval CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAOAK
CMC, Process Development & Tech Transfer Staffing FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)

Keywords

  • Pharmaceutical consulting services
  • Radiopharmaceutical manufacturing
  • Cell gene therapy consulting
  • Advanced therapy manufacturing
  • GMP regulatory compliance

Where Orchestra Life Sciences is headquartered

Location

Headquarters

HQ city
Creve Coeur
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Orchestra Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Technical Consulting Services: The company provides strategic support and scientific expertise to advance pharmaceutical therapies for cancer and rare disease. Services include business strategy, engineering solutions, process and analytical development, capital projects, supply chain, quality and regulatory, and operations excellence. Revenue is generated through consulting engagements, project-based work, and ongoing advisory relationships with clients in the advanced therapy sector.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Orchestra Life Sciences product offering

Product offering

Core offering

Orchestra Life Sciences is a technical consultancy providing strategic support and scientific expertise to pharmaceutical companies developing advanced therapies. Its core offering spans seven integrated service lines—Business Strategy, Engineering Solutions, Process & Analytical Development, Capital Projects, Supply Chain, Quality & Regulatory, and Operations Excellence—delivered alongside an ATMP Laboratory Services division and a Workforce Development Center for advanced therapy manufacturing talent.

Product overview

Orchestra Life Sciences is a technical consultancy offering a unified portfolio of strategic and scientific services organized around the core mission of advancing pharmaceutical therapies for cancer and rare disease. The company's offerings span seven integrated service lines — Business Strategy, Engineering Solutions, Process & Analytical Development, Capital Projects, Supply Chain, Quality & Regulatory, and Operations Excellence — which together provide end-to-end support from early-stage development through commercial-scale manufacturing. Supporting these service lines are educational resources (the Radiopharma Brochure and Cyclotron Ebook), a dedicated ATMP Laboratory Services division for process and bioanalytical development, and a Workforce Development Center launching in 2026 to address talent gaps in advanced therapy manufacturing. The services are designed to be delivered in concert, with each capability reinforcing the others to enable clients to move therapies from concept to commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

  • Business Strategy Consulting Strategic consulting service helping advanced therapy developers align business strategies, regulatory approaches, engineering processes, and go-to-market plans; designed for pharmaceutical and biotech companies in nuclear medicine, radiation oncology, cell and gene therapy, regenerative medicine, and biotechnology.
  • Engineering Solutions Engineering consulting supporting facility design, construction, and optimization for advanced therapy manufacturing, including hot cells, cyclotrons, isolators, containment systems, and process skids; intended for pharmaceutical and biotech companies building advanced therapy facilities.
  • Process & Analytical Development Technical consulting for process development and analytical method development across cell therapy, gene therapy, and radiopharmaceuticals from conception through commercialization; aimed at developers needing manufacturing process and analytical readiness.
  • Capital Projects End-to-end capital project solutions for specialized advanced therapy facilities, taking projects from feasibility studies through cGMP qualification while optimizing regulatory compliance, costs, and timelines; intended for pharmaceutical and biotech developers building or expanding manufacturing capacity.
  • Supply Chain Consulting Supply chain planning and optimization for radiopharmaceutical and advanced therapy programs, including isotope sourcing strategy for Ac-225, Lu-177, and Pb-212; serves developers needing reliable access to scarce isotopes and raw materials.
  • Quality & Regulatory Services Comprehensive quality, compliance, and regulatory affairs services including FDA compliance, ICH standards alignment, GMP audits, quality management system implementation, regulatory pathway development, and IND/IMPD/BLA submission support; serves developers of advanced therapies including radiopharmaceuticals, cell and gene therapies, and biologics.
  • Operations Excellence Consulting to drive operational efficiency, scalable processes, and repeatable execution frameworks for GMP-regulated advanced therapy manufacturing environments; serves developers scaling from clinical to commercial production.
  • ATMP Laboratory Services Process and analytical development and laboratory services for advanced therapeutic medicinal products (ATMPs) including cell therapy, gene therapy, and biologics; covers bioanalytical assays such as potency assays, flow cytometry, cell-based assays, and cell banking for developers needing laboratory support.
  • Workforce Development Center A specialized workforce development platform providing hands-on training for operations, quality control, and quality assurance roles in cell and gene therapy, radiopharmaceutical manufacturing, and nuclear medicine production; co-located with Orchestra's Philadelphia Navy Yard headquarters and aimed at addressing the nationwide shortage of production operators and QA/QC technicians.
  • TAG1 Generator A proprietary generator designed to unlock the supply of Lead-212 (Pb-212) for pre-clinical and clinical trials of targeted alpha therapies in cancer treatment; supports Orchestra's radiopharmaceutical clients and partners such as Precirix.

Quantifiable outcome

  • Expanded from 4-person team to 60+ employees and consultants within 3 years
  • +2 more outcomes

Companies that use Orchestra Life Sciences

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Orchestra Life Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Orchestra Life Sciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • BioCentriqcoreImplementation/ SI/ Consulting Partner · 14 January 2025Strategic partnership to support BioCentriq's Princeton, NJ cell therapy facility development. Orchestra provides comprehensive technical expertise for facility design, implementation of advanced manufacturing technologies, development of integrated digital ecosystem, and optimization of facility design to meet FDA and EU GMP regulatory requirements. The collaboration supports BioCentriq's $12M CAPEX investment for facility optimization and digital integration to enhance cell therapy development and GMP manufacturing capabilities.
  • Life CourierscoreStrategic or Co-development Partner · 17 September 2024Strategic partnership to enhance supply chain capabilities for the distribution of life-saving cancer treatments. Life Couriers, a global leader in specialized healthcare logistics, brings expertise in time-sensitive transport of medical isotopes and radiopharmaceuticals. The partnership leverages Life Couriers' global logistics network and Control Towers for real-time monitoring to streamline logistics between therapy developers and patients, minimizing delays and ensuring timely delivery of advanced therapies.
  • PrecirixcoreStrategic or Co-development Partner · 8 July 2024Strategic collaboration to expand access to Lead-212 (Pb-212) radioisotope for targeted alpha therapy in cancer treatment. Orchestra's TAG1 generator is designed to unlock Pb-212 supply for pre-clinical and clinical trials. The partnership combines Precirix's precision radiopharmaceutical expertise using camelid single-domain antibodies with Orchestra's proficiency in isotope production, driving new R&D initiatives and breakthroughs in cancer therapy.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Orchestra Life Sciences competitors and assessment

Company assessment

Broad incumbents

  • Parexel: Large global CRO offering regulatory consulting, CMC, clinical development, and commercialization services. Overlaps with Orchestra's regulatory and CMC work, but at vastly greater scale and across broader therapeutic areas.
  • IQVIA: World's largest CRO with broad regulatory, quality, and technology services for pharma. Comparable on regulatory/CMC consulting but serves a much wider client base and modality set than Orchestra.
  • Exyte: Global high-tech facility engineering and construction firm with a large life sciences practice. Comparable to Orchestra's Engineering Solutions and Capital Projects offerings for GMP and radiopharma facility builds, but at materially greater scale.

Direct peers

  • ProPharma Group: Regulatory, compliance, and quality consulting firm supporting pharma, biotech, and medical device companies. Closely matches Orchestra's CMC/regulatory and quality systems offering for advanced therapy developers.
  • CRB: Engineering, architecture, and consulting firm specializing in life sciences facility design and construction. Directly comparable to Orchestra's Engineering Solutions, Capital Projects, and Operations Excellence service lines, especially for advanced therapy and GMP facility work.
  • Precision for Medicine: Specialized services and CDMO supporting radiopharmaceutical, cell therapy, and biomarker-driven programs. Directly comparable to Orchestra's radiopharma and cell/gene therapy manufacturing consulting practice.
  • NDA Group: Independent regulatory and CMC consulting firm serving pharma and biotech globally. Comparable to Orchestra's Quality & Regulatory and Process & Analytical Development services, particularly for novel modalities and ATMPs.
  • Pharmalex: Regulatory affairs and quality compliance consulting firm serving pharma and biotech. Comparable to Orchestra's Quality & Regulatory Services line, including CMC, IND/IMPD/BLA support, and GxP compliance work.
  • Arcondis Group: Life sciences consulting firm offering regulatory, quality, engineering, and digital services to pharma and biotech. Overlaps with Orchestra's integrated seven-service platform for advanced therapy manufacturers.

Emerging players

  • Skillpad: Life sciences training and workforce development provider for pharma manufacturing. Comparable to Orchestra's planned Workforce Development Center for cell/gene therapy and radiopharma operators, although Skillpad is more established in the UK and Europe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Orchestra Life Sciences social profiles

Digital presence

Orchestra Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Orchestra Life Sciences leadership team

Management profile

Number of profiles

Profiles14 records

Orchestra Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Orchestra Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orchestra Life Sciences

What does Orchestra Life Sciences do?

Orchestra Life Sciences is a technical consultancy providing strategic support and scientific expertise to pharmaceutical companies developing advanced therapies. Its core offering spans seven integrated service lines—Business Strategy, Engineering Solutions, Process & Analytical Development, Capital Projects, Supply Chain, Quality & Regulatory, and Operations Excellence—delivered alongside an ATMP Laboratory Services division and a Workforce Development Center for advanced therapy manufacturing talent.

Is Orchestra Life Sciences a public or private company?

Orchestra Life Sciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Orchestra Life Sciences founded?

Orchestra Life Sciences was founded in 2023. It employs 51 to 100 people.

Where is Orchestra Life Sciences based?

Orchestra Life Sciences is headquartered in Creve Coeur, United States, in the North America region.

How does Orchestra Life Sciences make money?

One revenue line is on record: technical Consulting Services.

Who are Orchestra Life Sciences's main competitors?

Broad incumbents on record are Parexel, IQVIA and Exyte. Direct peers are ProPharma Group, CRB, Precision for Medicine, NDA Group, Pharmalex and Arcondis Group. Skillpad is listed as an emerging player.

Does Orchestra Life Sciences have an API?

No public API is recorded for Orchestra Life Sciences.

What industry is Orchestra Life Sciences in?

Orchestra Life Sciences's product category is Life Sciences Technical Consulting. Its primary akta.pro industry code is HLAGAKAB, CMC Regulatory Affairs (Modules 2/3, Variations, Post-Approval CMC), with a secondary code of HLAGAOAK, CMC, Process Development & Tech Transfer Staffing FSP. Its NAICS code is 54169 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireOrchestra Life Sciences Appoints Charles Conroy as Chief Operating OfficerOrchestra Life Sciences appointed Charles Conroy as Chief Operating Officer, bringing over 25 years of radiopharmaceutical and healthcare leadership. He previously founded Nucleus RadioPharma and led ARTMS Products, growing its enterprise value from $3 million to $82 million. The appointment aims to strengthen operational and capital decisions for client manufacturing facilities.PR NewswireOrchestra Life Sciences Named No. 203 on the 2026 Inc. 5000 List of America's Fastest-Growing Private CompaniesOrchestra Life Sciences was ranked No. 203 on the 2026 Inc. 5000 list of fastest-growing private companies, based on 1,482.8% revenue growth from 2022 to 2025. The company, a technical consultancy for advanced therapy manufacturing, expanded from four to nearly 100 employees over five years.PR NewswireOrchestra Life Sciences Expands into Europe to Support Radiopharmaceutical Execution, Appoints Vinod Ramnandanlal as President and Managing DirectorOrchestra Life Sciences announced the expansion of its European presence to support advanced therapy and radiopharmaceutical programs operating across global markets, appointing Vinod Ramnandanlal as President and Managing Director of OLS Europe. The expansion addresses growing demand for integrated execution, infrastructure readiness, and manufacturing strategy as more development and commercialization programs span North American and European operations. Vinod brings over a decade of board-level and executive experience in Europe, including previous service as Commercial Director and Executive Board member at NRG, a global leader in nuclear medical isotope production.BiobuzzOrchestra Life Sciences Relocates to Philadelphia Navy YardOrchestra Life Sciences is relocating its headquarters from Montreal to the Philadelphia Navy Yard, citing confidence in the region's advanced therapies ecosystem and workforce development. The company plans to establish a Workforce Development Center of Excellence at the site to train specialists in quality assurance and control for cell therapy and radiopharmaceutical manufacturing.PR NewswireOrchestra Life Sciences Relocates Global Headquarters to Philadelphia's Navy YardOrchestra Life Sciences announced the relocation of its global headquarters from Montreal, Quebec to Philadelphia, Pennsylvania at the Navy Yard, positioning the company at the center of a major life sciences hub. The company has grown from 4 employees to over 60 in three years and is launching a workforce development program in 2026 to address an estimated nationwide shortage of 400–600 production operators and 400–800 QA/QC technicians in cell and gene therapy and radiopharmaceutical manufacturing. PIDC, Philadelphia's public-private economic development corporation and master developer of the Navy Yard, will host the relocated headquarters at 1200 Intrepid Avenue.Roi-njBioCentriq partners with Orchestra Life Sciences to advance Princeton cell therapy facility developmentBioCentriq announced a partnership with Orchestra Life Sciences to support its Princeton cell therapy facility expansion. The collaboration backs a $12M CAPEX investment for facility optimization and digital integration, with Orchestra providing technical expertise. The partnership aims to complete the 60,000 sq. ft. facility by Q2 2025.PR NewswireBioCentriq Partners with Orchestra Life Sciences to Advance Princeton, NJ Cell Therapy Facility DevelopmentBioCentriq announced a partnership with Orchestra Life Sciences to support its $12M CAPEX investment in a new 60,000 sq. ft. Princeton, NJ cell therapy facility. The collaboration focuses on facility design, digital infrastructure, and GMP manufacturing capabilities, with completion targeted for Q2 2025.